K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients

AIDS

Volumn 19, Issue 16, 2005, Pages 1916-1919

  Gupta, Ravindra K ^a   Chrystie, Ian L ^a   O'Shea, Siobhan ^a   Mullen, Jane E ^a   Kulasegaram, Ranjababu ^a   Tong, Cheuk Y W ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVERSE TRANSCRIPTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT FAILURE; VIRUS DETECTION; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 27544479497     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000189860.36688.e5     Document Type: Article

References (18)

1. Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J, and the WHO-UNAIDS Network for HIV Isolation and Characterization. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002; 29:184-190.
2. Kantor R, Katzenstein D. Polymorphisms in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution. AIDS Rev 2003; 5:25-35.
3. Turner D, Brenner B, Moisi D, Detorio M, Cesaire R, Kurimura T, et al. Nucleotide and amino acid Polymorhisms at drug resistance sites in non-B subtype variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:2993-2998.
4. Frater AJ, Beardall A, Ariyoshi K, Churchill D, Galpin S, Clarke J R, et al. Impact of baseline polymorhisms in RT and protease on outcome of highly active retroviral therapy in HIV-1 infected African patients. AIDS 2001; 15:1493-1502.
5. Pillay D, Walker AS, Gigg DM, de Rossi A, Kaye S, Ait-Khaled M, et al. Impact of human immunodeficiency virus type 1 subtypes on virological response and emergence of drug resistance among children in the Paediatric European Network for treatment of AIDS (PENTA) 5 trial. J Infect Dis 2002; 186:617-625.
6. Montes B, Vergne L, Peeters M, Reynes J, Delaporte E, Segondy M. Comparison of drug resistance mutations and their interpretation in patients infected with non-B HIV-1 variants and matched patients infected with HIV-1 subtype B. J Acquir Immune Defic Syndr 2004; 35:329-336.
7. Cheung PK, Wynhoven B, Harrigan PR. 2004: which HIV-1 drug resistance mutations are common in clinical practice? AIDS Rev 2004; 6:107-116.
8. Valer L, Martin-Carbonero L, de Mendoza C, Corral A, Soriano V. Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations. AIDS 2004; 18:2094-2096.
9. Tong CYW, Mullen J, de Ruiter A, Kulasegaram R, O'Shea S, Chrystie IL. Genotyping of B and non-B subtypes of human immunodeficiency virus type 1. J Clin Microbiol 2005; 43:4623-4627.
10. Miller MD, Margot N, Lu B, Zhong L, Chen SS, Cheng A, et al. Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients. J Infect Dis 2004; 189:837-846.
11. Kagan RM, Merigan TC, Winters MA, Heseltine PN. Increasing prevalence of HIV-1 reverse transcriptase mutation K65R correlates with tenofovir utilization. Antivir Ther 2004; 9:827-828.
12. Gallant JE, Deresinski S. Tenofovir disoproxil fumarate. Clin Infect Dis 2003; 37:944-950.
13. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68:1660-1666.
14. Bacheler L, Jeffrey S, Hanna G, d'Aquila R, Wallace L, Logue K, et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001; 75:4999-5008.
15. Hoogewerf M, Regez RM, Schouten WE, Weigel HM, Frissen PH, Brinkman K. Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression. Lancet 2003; 362:1979-1980.
16. Leon A, Martinez E, Mallolas J, Laguno M, Blanco JL, Pumarola T, et al. Early virological failure in treatment-naive HIV-infected adults receiving didanosine and tenofovir plus efavirenz or nevirapine. AIDS 2005; 19:213-215.
17. Rouet F, Chaix ML, Inwoley A, Msellati P, Viho I, Combe P, et al. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Cote d'Ivoire: the ANRS 1236 study. J Med Virol 2004; 74:34-40.
18. Eshleman SH, Hoover D, Chen S, Hudelson S, Guay L, Mwatha A, et al. Comparison of nevirapine resistance in women with subtype C compared with subtypes A and D after single-dose NVP. In: 12th Conference on Retroviruses and Opportunistic Infections. Boston, February 2005 [Abstract 799].